Listed Managed Investment Reports

Pengana Private Equity Trust - Provide Access to US Manager - Grosvenor Capital Management L.P. - Target Return of 8%-14%p.a.
Tuesday, March 19, 2019
Pengana Capital Limited, the Manager, will appoint Grosvenor Capital Management L.P. (“Grosvenor” or the “Investment Manager”) to manage the portfolio. Grosvenor is a US based alternative asset manager established in 1971 with in excess of US$52 billion of assets under management (AUM).
Download Report
The Ophir High Conviction Fund (ASX: OPH) - Fund Generated a Net Performance of 20.2% - Substantially Outperformed the Benchmark By 14.1% p.a. (Gross Pre-Tax NTA)
Tuesday, March 19, 2019
The Trust provides investors with a concentrated portfolio of high quality growth companies, selected as the ‘best ideas’ across the small and mid-cap coverage of the Ophir investment team. Specifically, the portfolio comprises 15-30 targeted portfolio positions
Download Report
Platinum Capital Limited (ASX: PMC) - Absolute Return, Long Biased - Global Equities - Excellent Track Record
Tuesday, March 19, 2019
There is a strong focus on capital preservation and the Manager has a successful track record on preserving capital in down markets. A track-record of relatively high, stable and fully franked dividends may also serve the needs of those investors in the latter stage of their investment lifecycle.
Download Report
Latest LIC News & Update on the Sector
Monday, November 5, 2018
Welcome to our latest LIC Monthly prepared by our Research Team based on data collected our Analysts on the Sector.
Download Report
Hearts and Minds Investments Limited (ASX code: HM1) - Portfolio of the Highest Conviction Stock Picks - From Select Group of Fund Managers - For Charitable Cause - Advancement of Medical Research
Sunday, October 14, 2018
The company offers a unique opportunity to gain access to a portfolio of the highest conviction ideas from a select group of fund managers with the added benefit of contributing to Australian medical research institutes to support the development of new and improved treatments across a range ofspecialities.
Download Report